MONTREAL, QUEBEC--(Marketwire - October 15, 2008) - MethylGene Inc. (TSX: MYG) today announced the administration of MGCD290 as a single agent to the first cohort of healthy adult volunteers in a Phase I clinical study. MGCD290 is an orally available fungal Hos2 inhibitor designed to be used in combination with azoles for the treatment of fungal infections. Azoles are a widely-prescribed class of drugs that comprise almost half of the approximately U.S. $5 billion worldwide antifungal market.
